Bristol-Myers Squibb launches Mandarin education campaign
Bristol-Myers Squibb launched its first Mandarin-language campaign earlier this month with a goal to target the Asian community in the US.
BMS makes Baraclude, a drug used for the treatment of hepatitis B. Estimates state that half of the chronic infections in the US are patients who are Asian or Pacific Islanders, according to the news release from BMS.
Mike Huckman at CNBC’s Pharma’s Market blog notes: ” … Nearly every major pharmaceutical company is talking about the importance of emerging markets to their future growth - i.e. China, India, Russia, etc. Bristol-Myers Squibb is focusing on an emerging market within a developed market.” (more after break) Read more »